Welcome to our dedicated page for Lexeo Therapeutics news (Ticker: LXEO), a resource for investors and traders seeking the latest updates and insights on Lexeo Therapeutics stock.
Lexeo Therapeutics, Inc. develops clinical-stage genetic medicines for cardiovascular diseases, with company updates centered on AAV-based gene therapy candidates and related cardiac delivery technology. Its portfolio includes LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2-associated arrhythmogenic cardiomyopathy.
Recurring developments include clinical data from cardiac gene therapy studies, FDA and CMC engagement, manufacturing work involving an optimized Sf9-baculovirus AAV platform, research collaborations for targeted cardiac delivery, quarterly financial results, conference presentations, and leadership or board changes tied to the company’s cardiovascular medicine focus.
Summary not available.
Summary not available.